Abstract
Introduction Certolizumab pegol (CZP), the Fc-free, PEGylated anti-tumor necrosis factor, is approved for the treatment of moderate to severe plaque p......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
